Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasia Mahdi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Nature Reviews. Immunology|October 6, 2025
The promise of immunotherapy for central nervous system tumoursJasia Mahdi, Vrunda Trivedi, Michelle Monje
Neurology|April 18, 2020
Nonoptic pathway tumors in children with neurofibromatosis type 1Jasia Mahdi, Manu S Goyal, Jennifer Griffith, et al.
Neurology. Clinical Practice|August 25, 2018
Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1Jennifer L Griffith, Stephanie M Morris, Jasia Mahdi, et al.
Stroke|July 4, 2015
Pediatric Acute Stroke Protocol Activation in a Children's Hospital Emergency DepartmentTravis R Ladner, Jasia Mahdi, Melissa C Gindville, et al.
Neurology|March 24, 2017
A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1Jasia Mahdi, Amish C Shah, Aimee Sato, et al.
Pediatric Neurology|February 20, 2015
A multispecialty pediatric neurovascular conference: a model for interdisciplinary management of complex diseaseTravis R Ladner, Jasia Mahdi, Albert Attia, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nature Reviews. Immunology|October 6, 2025
The promise of immunotherapy for central nervous system tumoursJasia Mahdi, Vrunda Trivedi, Michelle Monje
Neurology|April 18, 2020
Nonoptic pathway tumors in children with neurofibromatosis type 1Jasia Mahdi, Manu S Goyal, Jennifer Griffith, et al.
Neurology. Clinical Practice|August 25, 2018
Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1Jennifer L Griffith, Stephanie M Morris, Jasia Mahdi, et al.
Stroke|July 4, 2015
Pediatric Acute Stroke Protocol Activation in a Children's Hospital Emergency DepartmentTravis R Ladner, Jasia Mahdi, Melissa C Gindville, et al.
Neurology|March 24, 2017
A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1Jasia Mahdi, Amish C Shah, Aimee Sato, et al.
Pediatric Neurology|February 20, 2015
A multispecialty pediatric neurovascular conference: a model for interdisciplinary management of complex diseaseTravis R Ladner, Jasia Mahdi, Albert Attia, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 1